Abstract

 

Abstract

 

Thyroid carcinoma (TC) is the most common endocrine malignancy. Although the overall prognosis for patients with TC is good, up to 20-30% of patients have recurrent or persistent disease after conventional therapy by surgical resection and radioactive iodine (RAI).Amiodarone is a highly efficient anti-arrhythmic drug with a very long half-life, so it may interfere with RAI many months after the drug withdrawal.This case report mirrors the challenges of thyroid cancer management in an amiodarone-treated patient.

 

Keywords

thyroid cancer, amiodarone, lymph nodes dissection, radioiodine